The primary objective of this single-center study is to demonstrate the performance of cCeLL, used in real time, compared to frozen section analysis. The investigational device is intended for use with indocyanine green (ICG) for fluorescence imaging as an aid in the visualization of vessels (micro- and macro-vasculature) blood flow in the cerebrovascular before, during or after cranial diagnostic and therapeutic procedures, such as tumor biopsy and resection, and the images will be immediately transmitted to a single pathologist for real-time evaluation, without influencing the surgical decision-making process. The comparison will be made between the device and the conventional intraoperative histological frozen section analysis of identical brain tissue samples in the same patient. Both methods will be compared in terms of their accuracy using the standard of practice, the final pathological diagnosis.

Inclusion Criteria:

1. Male or female patients aged 18 years or older as of the screening date
2. Patients suspected of having a brain tumor who are scheduled for neurosurgery and are considered candidates for tumor resection
3. Patients who understand and have signed the informed consent form

Exclusion Criteria:

1. Specimens obtained from patients who have agreed to participate in this clinical trial and who meet the inclusion criteria
2. Normal tissue specimens obtained unavoidably during tumor resection surgery in tumor patients
3. Tissue samples must be adequate for both FS and PS analysis
4. Minimum lesion size of 1 cm for reliable cCeLL imaging

Individual Participant Data (IPD) may not be shared due to patient privacy concerns, confidentiality agreements, regulatory restrictions, ethical considerations, and institutional policies. Additionally, data protection laws (e.g., GDPR, HIPAA) and proprietary research interests may limit data availability to ensure compliance and safeguard participant information.

Pathologists will perform diagnoses without access to patient medical records and will not see prior diagnostic results. They will assess tissue samples using only de-identified information, ensuring that fluorescence imaging results do not influence their evaluation. This approach eliminates bias and maintains the integrity of the study's diagnostic comparison.